What is Genuity Science?
Headquartered in Ireland, Genuity Science operates at the intersection of advanced genomics and data-driven medicine. The company provides an end-to-end suite of services that encompasses the entire lifecycle of biological research, including sample processing, biobanking, nucleic acid extraction, and rigorous quality control. Furthermore, their expertise in next-generation sequencing, methylation profiling, and secure data delivery positions them as a critical partner for pharmaceutical and clinical research organizations. By streamlining the path from raw biological samples to actionable insights, Genuity Science facilitates the acceleration of precision medicine and therapeutic discovery on a global scale.
How much funding has Genuity Science raised?
Genuity Science has raised a total of $620M across 4 funding rounds:
Series A
$15M
Series B
$165M
Unspecified
$240M
Series C
$200M
Series A (2013): $15M with participation from Polaris Partners and ARCH Venture Partners
Series B (2017): $165M led by Temasek, Amgen Business Development, Sequoia China, Yunfeng Capital, and 3W Partners
Unspecified (2017): $240M supported by Steamboat Ventures, Temasek, 3W Partners, and Yunfeng Capital
Series C (2018): $200M featuring Steamboat Ventures, Ireland Strategic Investment Fund, Temasek, and Yunfeng Capital
Key Investors in Genuity Science
Temasek
A global investment company headquartered in Singapore with a significant portfolio in life sciences and innovative technology sectors.
Steamboat Ventures
A venture capital firm that focuses on identifying and supporting high-growth companies within the media, technology, and consumer sectors.
Yunfeng Capital
A prominent private equity firm that specializes in growth-stage investments across diverse industries, including healthcare and biotechnology.
What's next for Genuity Science?
With the recent influx of capital, Genuity Science is well-positioned to expand its technological footprint and enhance its data processing capabilities. The strategic focus will likely shift toward deepening its integration within the global pharmaceutical R&D ecosystem, leveraging its robust infrastructure to support increasingly complex clinical trials. As the demand for high-fidelity genomic data continues to rise, the company is expected to prioritize the scaling of its sequencing throughput and the refinement of its proprietary data analytics platforms. This phase of growth will be critical in maintaining its competitive advantage in the rapidly evolving landscape of genomic research and personalized healthcare solutions.
See full Genuity Science company page
